In recent years, the progress of NAFLD has become an important health problem, and the prevention or delay of progress in NAFLD is a major key point. Whether or not to combine T2MD, people are interested in the mechanisms and efficacy of SGLT2i for NAFLD. In this review, we summarized the current clinical research on SGLT2i for the combination of T2MD’s NAFLD patients, and the latest evidence of external or animal experiments. These evidences will help us to more accurately understand the protective effects of SGLT2i in NAFLD. Lifestyle changes are still essential to prevent and treat NAFLD, and for all kinds of drugs that treat NAFLD in clinical trials, SGLT2i may be one of the promising treatments.
References
[1]
Younossi, Z., et al. (2019) Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Hepatology, 69, 2672-2682. https://doi.org/10.1002/hep.30251
[2]
Fang, Y.L., Chen, H., Wang, C.L., et al. (2018) Pathogenesis of Non-Alcoholic Fatty Liver Disease in Children and Adolescence: From “Two Hit Theory” to “Multiple Hit Model”. World Journal of Gastroenterology, 24, 2974-2983. https://doi.org/10.3748/wjg.v24.i27.2974
[3]
Bhatt, H.B. and Smith, R.J. (2015) Fatty Liver Disease in Diabetes Mellitus. Hepatobiliary Surgery and Nutrition, 4, 101-108.
[4]
Riazi, K., et al. (2022) The Prevalence and Incidence of NAFLD Worldwide: A Systematic Review and Meta-Analysis. The Lancet Gastroenterology and Hepatology, 7, 851-861. https://doi.org/10.1016/S2468-1253(22)00165-0
[5]
Cigrovski Berkovic, M., Virovic-Jukic, L., Bilic-Curcic, I. and Mrzljak, A. (2020) Post-Transplant Diabetes Mellitus and Preexisting Liver Disease—A Bidirectional Relationship Affecting Treatment and Management. World Journal of Gastroenterology, 26, 2740-2757. https://doi.org/10.3748/wjg.v26.i21.2740
[6]
Meyhofer, S., et al. (2022) Elevated Liver Enzymes and Comorbidities in Type 2 Diabetes: A Multicentre Analysis of 51 645 Patients from the Diabetes Prospective Follow-Up (DPV) Database. Diabetes, Obesity and Metabolism, 24, 727-732. https://doi.org/10.1111/dom.14616
[7]
Davidson, J.A. and Kuritzky, L. (2014) Sodium Glucose Co-Transporter 2 Inhibitors and Their Mechanism for Improving Glycemia in Patients with Type 2 Diabetes. Postgraduate Medicine, 126, 33-48. https://doi.org/10.3810/pgm.2014.10.2819
[8]
Ala, M. (2021) SGLT2 Inhibition for Cardiovascular Diseases, Chronic Kidney Disease, and NAFLD. Endocrinology, 162, bqab157. https://doi.org/10.1210/endocr/bqab157
[9]
Belfort-DeAguiar, R., Lomonaco, R. and Cusi, K. (2023) Approach to the Patient with Nonalcoholic Fatty Liver Disease. The Journal of Clinical Endocrinology & Metabolism, 108, 483-495. https://doi.org/10.1210/clinem/dgac624
[10]
Marjot, T., et al. (2020) Sodium-Glucose Cotransporter 2 Inhibition Does Not Reduce Hepatic Steatosis in Overweight, Insulin-Resistant Patients without Type 2 Diabetes. JGH Open, 4, 433-440. https://doi.org/10.1002/jgh3.12274
[11]
Ehrenkranz, J.R., Lewis, N.G., Kahn, C.R. and Roth, J. (2005) Phlorizin: A Review. Diabetes/Metabolism Research and Reviews, 21, 31-38. https://doi.org/10.1002/dmrr.532
[12]
Fujita, Y. and Inagaki, N. (2014) Renal Sodium Glucose Cotransporter 2 Inhibitors as a Novel Therapeutic Approach to Treatment of Type 2 Diabetes: Clinical Data and Mechanism of Action. Journal of Diabetes Investigation, 5, 265-275. https://doi.org/10.1111/jdi.12214
[13]
Hameed, I., et al. (2023) Comparison of Sodium-Glucose Cotransporter-2 Inhibitors and Thiazolidinediones for Management of Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Clinics and Research in Hepatology and Gastroenterology, 47, Article ID: 102111. https://doi.org/10.1016/j.clinre.2023.102111
[14]
Arase, Y., et al. (2019) Effect of Sodium Glucose Co-Transporter 2 Inhibitors on Liver Fat Mass and Body Composition in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus. Clinical Drug Investigation, 39, 631-641. https://doi.org/10.1007/s40261-019-00785-6
[15]
Cusi, K., et al. (2019) Effect of Canagliflozin Treatment on Hepatic Triglyceride Content and Glucose Metabolism in Patients with Type 2 Diabetes. Diabetes, Obesity and Metabolism, 21, 812-821. https://doi.org/10.1111/dom.13584
[16]
Horibe, K., et al. (2022) Metabolic Changes Induced by Dapagliflozin, an SGLT2 Inhibitor, in Japanese Patients with Type 2 Diabetes Treated by Oral Anti-Diabetic Agents: A Randomized, Clinical Trial. Diabetes Research and Clinical Practice, 186, Article ID: 109781. https://doi.org/10.1016/j.diabres.2022.109781
[17]
Sakurai, S., et al. (2020) Empagliflozin Decreases the Plasma Concentration of Plasminogen Activator Inhibitor-1 (PAI-1) in Patients with Type 2 Diabetes: Association with Improvement of Fibrinolysis. Journal of Diabetes and Its Complications, 34, Article ID: 107703. https://doi.org/10.1016/j.jdiacomp.2020.107703
[18]
Ng, C.H., et al. (2022) Antidiabetic Medications for Type 2 Diabetics with Nonalcoholic Fatty Liver Disease: Evidence from a Network Meta-Analysis of Randomized Controlled Trials. Endocrine Practice, 28, 223-230. https://doi.org/10.1016/j.eprac.2021.09.013
[19]
Akuta, N., et al. (2017) Effects of a Sodium-Glucose Cotransporter 2 Inhibitor in Nonalcoholic Fatty Liver Disease Complicated by Diabetes Mellitus: Preliminary Prospective Study Based on Serial Liver Biopsies. Hepatology Communications, 1, 46-52. https://doi.org/10.1002/hep4.1019
[20]
Lai, L.L., et al. (2020) Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus. Digestive Diseases and Sciences, 65, 623-631. https://doi.org/10.1007/s10620-019-5477-1
[21]
Takahashi, H., et al. (2022) Ipragliflozin Improves the Hepatic Outcomes of Patients with Diabetes with NAFLD. Hepatology Communications, 6, 120-132. https://doi.org/10.1002/hep4.1696
[22]
Arai, T., et al. (2022) Antifibrotic Effect and Long-Term Outcome of SGLT2 Inhibitors in Patients with NAFLD Complicated by Diabetes Mellitus. Hepatology Communications, 6, 3073-3082. https://doi.org/10.1002/hep4.2069
[23]
Bellanti, F., et al. (2022) Impact of Sodium Glucose Cotransporter-2 Inhibitors on Liver Steatosis/Fibrosis/Inflammation and Redox Balance in Non-Alcoholic Fatty Liver Disease. World Journal of Gastroenterology, 28, 3243-3257. https://doi.org/10.3748/wjg.v28.i26.3243
[24]
Euh, W., Lim, S. and Kim, J.W. (2021) Sodium-Glucose Cotransporter-2 Inhibitors Ameliorate Liver Enzyme Abnormalities in Korean Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease. Frontiers in Endocrinology, 12, Article 613389. https://doi.org/10.3389/fendo.2021.613389
[25]
Xing, B., et al. (2020) Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials. Journal of Diabetes Investigation, 11, 1238-1247. https://doi.org/10.1111/jdi.13237
[26]
Akuta, N., et al. (2022) Favorable Impact of Long-Term SGLT2 Inhibitor for NAFLD Complicated by Diabetes Mellitus: A 5-Year Follow-Up Study. Hepatology Communications, 6, 2286-2297. https://doi.org/10.1002/hep4.2005
[27]
Chiang, H., et al. (2020) Delayed Intervention with a Novel SGLT2 Inhibitor NGI001 Suppresses Diet-Induced Metabolic Dysfunction and Non-Alcoholic Fatty Liver Disease in Mice. British Journal of Pharmacology, 177, 239-253. https://doi.org/10.1111/bph.14859
[28]
Honda, Y., et al. (2016) The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in Mice. PLOS ONE, 11, e0146337. https://doi.org/10.1371/journal.pone.0146337
[29]
Hüttl, M., et al. (2021) In a Prediabetic Model, Empagliflozin Improves Hepatic Lipid Metabolism Independently of Obesity and before Onset of Hyperglycemia. International Journal of Molecular Sciences, 22, Article 11513. https://doi.org/10.3390/ijms222111513
[30]
David-Silva, A., et al. (2020) Dual SGLT1/SGLT2 Inhibitor Phlorizin Ameliorates Non-Alcoholic Fatty Liver Disease and Hepatic Glucose Production in Type 2 Diabetic Mice. Diabetes, Metabolic Syndrome and Obesity, 13, 739-751. https://doi.org/10.2147/DMSO.S242282
[31]
Nasiri-Ansari, N., et al. (2021) Empagliflozin Attenuates Non-Alcoholic Fatty Liver Disease (NAFLD) in High Fat Diet Fed ApoE(-/-) Mice by Activating Autophagy and Reducing ER Stress and Apoptosis. International Journal of Molecular Sciences, 22, Article 818. https://doi.org/10.3390/ijms22020818
[32]
Meng, Z., et al. (2021) The SGLT2 Inhibitor Empagliflozin Negatively Regulates IL-17/IL-23 Axis-Mediated Inflammatory Responses in T2DM with NAFLD via the AMPK/mTOR/Autophagy Pathway. International Immunopharmacology, 94, Article ID: 107492. https://doi.org/10.1016/j.intimp.2021.107492
[33]
Petito-da-Silva, T.I., Souza-Mello, V. and Barbosa-da-Silva, S. (2019) Empaglifozin Mitigates NAFLD in High-Fat-Fed Mice by Alleviating Insulin Resistance, Lipogenesis and ER Stress. Molecular and Cellular Endocrinology, 498, Article ID: 110539. https://doi.org/10.1016/j.mce.2019.110539
[34]
Yoshioka, N., et al. (2021) The Sodium-Glucose Cotransporter-2 Inhibitor Tofogliflozin Prevents the Progression of Nonalcoholic Steatohepatitis-Associated Liver Tumors in a Novel Murine Model. Biomedicine & Pharmacotherapy, 140, Article ID: 111738. https://doi.org/10.1016/j.biopha.2021.111738
[35]
Wong, C., et al. (2020) Sodium-Glucose Co-Transporter 2 Inhibitors for Non-Alcoholic Fatty Liver Disease in Asian Patients with Type 2 Diabetes: A Meta-Analysis. Frontiers in Endocrinology, 11, Article 609135. https://doi.org/10.3389/fendo.2020.609135
[36]
Mantovani, A., et al. (2020) Efficacy and Safety of Anti-Hyperglycaemic Drugs in Patients with Non-Alcoholic Fatty Liver Disease with or without Diabetes: An Updated Systematic Review of Randomized Controlled Trials. Diabetes & Metabolism, 46, 427-441. https://doi.org/10.1016/j.diabet.2019.12.007
[37]
Koufakis, T., et al. (2022) From Skepticism to Hope: The Evolving Concept of the Initiation and Use of Sodium-Glucose Cotransporter 2 Inhibitors in Hospitalized Patients. Drugs, 82, 949-955. https://doi.org/10.1007/s40265-022-01730-2
[38]
Li, B., et al. (2018) Effects of Canagliflozin on Fatty Liver Indexes in Patients with Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials. Journal of Pharmacy & Pharmaceutical Sciences, 21, 222-235. https://doi.org/10.18433/jpps29831
[39]
Coelho, F.D.S., et al. (2021) Effects of Sodium-Glucose Co-Transporter 2 Inhibitors on Liver Parameters and Steatosis: A Meta-Analysis of Randomized Clinical Trials. Diabetes/Metabolism Research and Reviews, 37, e3413. https://doi.org/10.1002/dmrr.3413
[40]
Bica, I.C., et al. (2023) The Effects of Sodium-Glucose Cotransporter 2-Inhibitors on Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease or Steatohepatitis and Type 2 Diabetes: A Systematic Review of Randomized Controlled Trials. Medicina, 59, Article 1136. https://doi.org/10.3390/medicina59061136
[41]
Hsu, S.J., et al. (2022) Sodium-Glucose Cotransporter-2 Inhibition Exacerbates Hepatic Encephalopathy in Biliary Cirrhotic Rats. Journal of Pharmacology and Experimental Therapeutics, 383, 25-31. https://doi.org/10.1124/jpet.122.001289
[42]
Palmer, S.C., et al. (2021) Sodium-Glucose Cotransporter Protein-2 (SGLT-2) Inhibitors and Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists for Type 2 Diabetes: Systematic Review and Network Meta-Analysis of Randomised Controlled Trials. BMJ, 372, m4573.
[43]
Qiu, M., Ding, L.L., Zhang, M. and Zhou, H.R. (2021) Safety of Four SGLT2 Inhibitors in Three Chronic Diseases: A Meta-Analysis of Large Randomized Trials of SGLT2 Inhibitors. Diabetes & Vascular Disease Research, 18, 1-3. https://doi.org/10.1177/14791641211011016
[44]
Dong, B., et al. (2022) The Extraglycemic Effect of SGLT-2is on Mineral and Bone Metabolism and Bone Fracture. Frontiers in Endocrinology, 13, Article 918350. https://doi.org/10.3389/fendo.2022.918350
[45]
Tokushige, K., et al. (2021) Evidence-Based Clinical Practice Guidelines for Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis 2020. Hepatology Research, 51, 1013-1025. https://doi.org/10.1111/hepr.13688
